Patent Assignment
Reel/Frame 031531/0488
Patent Security Agreement
Recorded: 2013-10-31
Pages: 13
Assignors
APTALIS PHARMA CANADA INC.
Executed: 2013-10-04
APTALIS PHARMA US, INC.
Executed: 2013-10-04
APTALIS PHARMATECH, INC.
Executed: 2013-10-04
Assignee
BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
100 N. TRYON STREET, MAIL CODE: NC1-007-17-15, CHARLOTTE, NORTH CAROLINA, 28255
Covered Properties
(70)
Rapid Dissolve Tablet Compositions for Vaginal Administration
PCT:
PCT/US2012/036055 ↗
Supported Drugs with Increased Dissolution Rate, and a Process for Their Preparation
Patent:
5,449,521 →
Application:
08/203,034 →
Procedure for Encapsulating Chlorpheniramine
Patent:
5,622,723 →
Application:
08/383,033 →
Effervescent Microcapsules
Patent:
5,639,475 →
Application:
08/383,342 →
Controlled Release Potassium Tablet
Patent:
5,651,984 →
Application:
08/404,216 →
Innovative Technique for Immunosuppression Involving Administration of Rapamycin Loaded Formed Blood Elements
Patent:
5,622,963 →
Application:
08/423,182 →
Procedure for Encapsulating Ibuprofen
Patent:
5,653,993 →
Application:
08/483,909 →
Stable Aqueous Suspensions of Mesalazine
Patent:
5,731,302 →
Application:
08/722,720 →
Procedure for Encapsulating Ibuprofen
Patent:
5,814,332 →
Application:
08/804,091 →
Taste-Masked Microcapsule Compositions and Methods of Manufacture
Patent:
6,139,865 →
Application:
08/942,094 →
Functional Coating of Linezolid Microcapsules for Taste-Masking and Associated Formulation for Oral Administration
Patent:
6,451,345 →
Application:
09/506,051 →
Double Capsule for the Administration of Active Principles in Multiple Therapies
Patent:
6,350,468 →
Application:
09/581,721 →
Methylphenidate modified release formulations
Patent:
6,344,215 →
Application:
09/697,803 →
Timed Pulsatile Drug Delivery Systems
Timed, Sustained Release Systems for Propranolol
Patent:
6,500,454 →
Application:
09/971,167 →
Pulsatile Release Histamine H2 Antagonist Dosage Form
Extended Release Dosage Forms of Propranolol Hydrochloride
Timed, sustained release systems for propranolol
Controlled Release Potassium Chloride Tablets
Timed Pulsatile Drug Delivery Systems
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Timed, pulsatile release systems
Taste-masked pharmaceutical compositions prepared by coacervation
Application:
11/213,266 →
Publication:
US 2006/0105038
Orally disintegrating tablets of atomoxetine
Taste-Masked Pharmaceutical Compositions
Taste-Masked Pharmaceutical Compositions with Gastrosoluble Pore-Formers
Application:
11/256,653 →
Publication:
US 2006/0105039
Timed, Sustained Release Systems for Propranolol
Drug Delivery Systems Comprising Weakly Basic Selective Serotonin 5-HT3 Blocking Agent and Organic Acids
Application:
11/668,167 →
Publication:
US 2007/0190145
Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids
Application:
11/668,408 →
Publication:
US 2007/0196491
Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
Application:
11/847,219 →
Publication:
US 2008/0069878
Process for Preparation of Aldonic Acids and Derivatives Thereof
Application:
11/932,961 →
Publication:
US 2009/0112002
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Pharmaceutical Compositions Comprising an Active Substance from the Substituted Benzhydrylpiperazine Family
Orally Disintegrating Tablet Compositions of Lamotrigine
Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Mesalamine Suppository
Orally Disintegrating Tablet Compositions of Temazepam
Application:
12/339,908 →
Publication:
US 2009/0169620
Method for Detecting Infectious Parvovirus in Pharmaceutical Preparations
Compositions Comprising Weakly Basic Drugs and Controlled-Release Dosage Forms
Application:
12/424,201 →
Publication:
US 2009/0258066
Taste-Masked Pharmaceutical Compositions Prepared by Coacervation
Application:
12/466,855 →
Publication:
US 2009/0263480
Mesalamine Suppository
Preparation of Controlled Release Skeletal Muscle Relaxant Dosage Forms
Orally Disintegrating Tablet Compositions of Lamotrigine
Mesalamine Suppository
Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
Application:
12/688,493 →
Publication:
US 2011/0003005
Orally Disintegrating Tablet Compositions Comprising Combinations of High and Low-Dose Drugs
Application:
12/772,770 →
Publication:
US 2010/0330150
Orally Disintegrating Tablet Compositions Comprising Combinations of Non-Opioid and Opioid Analgesics
L-Sugar Colon Cleansing Agent and Uses Thereof
L-Sugar Colon Cleansing Agent and Uses Thereof
Orally Administered Corticosteroid Compositions
Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting
Application:
12/956,249 →
Publication:
US 2011/0135724
Compressible-Coated Pharmaceutical Compositions and Tablets and Methods of Manufacture
Application:
12/956,543 →
Publication:
US 2011/0129530
Taste Masked Topiramate Composition and an Orally Disintegrating Tablet Comprising the Same
Application:
12/986,457 →
Publication:
US 2011/0212171
Orally Disintegrating Tablets Comprising Diphenhydramine
Application:
13/183,125 →
Publication:
US 2012/0093938
Timed, Pulsatile Release Systems
Controlled Release Compositions Comprising Anti-Cholinergic Drugs
Application:
13/202,957 →
Publication:
US 2011/0311626
Controlled-Release Compositions Comprising a Proton Pump Inhibitor
Application:
13/202,959 →
Publication:
US 2012/0128764
Method of Treating Nonalcoholic Steatohepatitis with Elevated Doses of Ursodeoxycholic Acid
Application:
13/217,042 →
Publication:
US 2012/0071451
Rapidly Dispersing Granules, Orally Disintegrating Tablets and Methods
Application:
13/310,632 →
Publication:
US 2012/0282335
Preparation of Controlled Release Skeletal Muscle Relaxant Dosage Forms
Application:
13/371,967 →
Publication:
US 2012/0196028
Orally Disintegrating Tablet Compositions of Lamotrigine
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Methods for Purifying Monosaccharide Mixtures Containing Ionic Impurities
Application:
13/735,805 →
Publication:
US 2013/0338086
Latching Cam Handle Assembly for Securing Mated Circuit Boards
Gastro-Resistant Enzyme Pharmaceutical Compositions
Application:
13/874,903 →
Publication:
US 2013/0337062
Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
Orally Disintegrating Tablets and Methods of Manufacture
Related Assignments
(19)
Other recorded transfers of the patents in this record — the chain of ownership.
Change of Name
Aug 30, 2012
From: EURAND, INC.
To: APTALIS PHARMATECH, INC.
Reel/Frame 028884/0903 →
Change of Name
Sep 30, 2012
From: EURAND, INC.
To: APTALIS PHARMATECH, INC.
Reel/Frame 029058/0568 →
Change of Name
Nov 27, 2012
From: EURAND, INCORPORATED
To: APTALIS PHARMATECH, INC.
Reel/Frame 029361/0709 →
Release of Lien on Patents
Oct 24, 2013
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: APTALIS PHARMA CANADA INC.
Reel/Frame 031494/0933 →
Release of Lien on Patents
Oct 24, 2013
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: APTALIS PHARMATECH, INC.
Reel/Frame 031494/0925 →
Termination and Release
Jan 31, 2014
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: APTALIS PHARMA US, INC.; APTALIS PHARMATECH, INC.; APTALIS PHARMA CANADA INC.
Reel/Frame 032149/0111 →
Change of Name
Aug 5, 2015
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 036283/0261 →
Change of Name
Aug 6, 2015
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 036294/0319 →
Change of Name
Aug 18, 2015
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 036380/0942 →
Change of Name
Aug 18, 2015
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 036380/0893 →
Change of Name
Aug 18, 2015
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 036380/0926 →
Change of Name
Sep 18, 2015
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 036640/0591 →
Change of Name
Sep 25, 2015
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 036689/0358 →
U.S. Patent Security Agreement
Dec 8, 2015
From: ADARE PHARMACEUTICALS, INC.
To: BANK OF MONTREAL
Reel/Frame 037246/0313 →
Change of Name
Mar 18, 2016
From: APTALIS PHARMA CANADA INC.
To: APTALIS PHARMA CANADA ULC
Reel/Frame 038037/0424 →
Release of Security Interest
Dec 18, 2017
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: APTALIS PHARMA US, INC.; APTALIS PHARMATECH, INC.; APTALIS PHARMA CANADA INC.
Reel/Frame 044420/0296 →
Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276
Sep 22, 2020
From: BANK OF MONTREAL, AS COLLATERAL AGENT
To: ADARE PHARMACEUTICALS, INC.; ADARE DEVELOPMENT I, L.P.; ADARE PHARMACEUTICALS USA, INC.
Reel/Frame 053852/0697 →
Security Interest
Sep 22, 2020
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: CRESCENT AGENCY SERVICES LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 053849/0967 →
Security Interest
Nov 8, 2022
From: ADARE PHARMACEUTICALS, INC.; ADARE PHARMACEUTICALS USA, INC.
To: TEAL MIDCO HOLDINGS, L.P.
Reel/Frame 061698/0541 →